Biological matrices for the evaluation of in utero exposure to drugs of abuse

Therapeutic Drug Monitoring

Volumn 29, Issue 6, 2007, Pages 711-734

  Lozano, Jaime ^a,d   García Algar, Oscar ^a,d   Vall, Oriol ^a,d   De La Torre, Rafael ^b,e   Scaravelli, Giulia ^c   Pichini, Simona ^c  

^a HOSPITAL DEL MAR   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Biological matrices; Drugs of abuse; Exposure; Fetus

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; ARECOLINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABIS; COCAINE; DIAMORPHINE; METHADONE; OPIATE; PHENCYCLIDINE; XENOBIOTIC AGENT;

AMNION FLUID; ANALYTIC METHOD; BLOOD ANALYSIS; BODY FLUID; BREAST MILK; CHROMATOGRAPHY; CONCENTRATION RESPONSE; DRUG ABUSE; DRUG DETERMINATION; DRUG SCREENING; GAS CHROMATOGRAPHY; GESTATION PERIOD; HAIR ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MECONIUM; MEDICAL RECORD; METABOLITE; METHODOLOGY; PLACENTA; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; URINALYSIS;

DRUG MONITORING; FEMALE; FETUS; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; SUBSTANCE-RELATED DISORDERS;

EID: 36549049511     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815c14ce     Document Type: Review

References (112)

1. Harvey JA. Cocaine effects on the developing brain: current status. Neurosci Biobehav Rev. 2004;27:751-764.
2. Feng Q. Postnatal consequences of prenatal cocaine exposure and myocardial apoptosis: does cocaine in utero imperil the adult heart? Br J Pharmacol. 2005;144:887-888.
3. Huestis MA, Cone EJ. Alternative testing matrices. In: S. Karch, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press; 1998:799-857.
4. Huestis MA, Choo RE. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci Int. 2002;128:20-30.
5. Olsen GD. Placental permeability for drugs of abuse and their metabolites. NIDA Res Monogr. 1995;154:152-162.
6. Sastry BV. Placental toxicology: tobacco smoke, abused drugs, multiple chemical interactions, and placental function. Reprod Fertil Dev. 1991;3:355-372.
7. Chan D, Knie B, Boskovic R, et al. Placental handling of fatty acid ethyl esters: perfusion and subcellular studies. J Pharmacol Exp Ther. 2004;310:75-82.
8. Myllynen P. Human placenta: a human organ for developmental toxicology research and biomonitoring. Placenta. 2005;26:361-371.
9. Ostrea E, Porter T, Balun J, et al. Effect of chronic maternal drug addiction on placental drug metabolism. Dev Pharmacol Ther. 1989;12:42-48.
10. Garcia-Algar O, Vall O, Alameda F, et al. Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes. Arch Dis Child Fetal Neonatal Ed. 2005;90:F276-F277.
11. Lopez-Vilchez MA, Seidel V, Farre M, et al. Areca-nut abuse and neonatal withdrawal syndrome. Pediatrics. 2006;117:129-131.
12. Langman J, Sadler TW. Langman's Medical Embriology. Philadelphia: Williams & Wilkins; 1990;7:106-123.
13. Pichini S, Altieri I, Zuccaro P, et al. Drugs monitoring in non-conventional biological fluids and matrices. Clin Pharmacokinet. 1996;130:211-228.
14. Szeto HH. Kinetics of drug transfer to the fetus. Clin Obstet Gynecol. 1993;36:246-254.
15. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet. 1995;28:235-269.
16. Ripple GM, Goldberger BA, Caplan YH, et al. Detection of cocaine and its metabolites in human amniotic fluid. J Anal Toxicol. 1992;16:328-331.
17. Jain L, Meyer W, Moore C, et al. Detection of fetal cocaine exposure by analysis of amniotic fluid. Obstet Gynecol. 1993;81:787-790.
18. Eyler FD, Behnke M, Wobie K, et al. Relative ability of biologic specimens and interviews to detect prenatal cocaine use. Neurotoxicol Teratol. 2005;27:677-687.
19. Winecker RE, Goldberger BA, Tebbett I, et al. Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J Anal Toxicol. 1997;21:97-104.
20. Gareri J, Klein J, Koren G. Drugs of abuse testing in meconium. Clin Chim Acta. 2006;366:101-111.
21. Pichini S, Altieri I, Zuccaro P, et al. Meconium as a matrix. Clin Pharmacokinet. 1996;131:81.
22. Ostrea EM Jr, Parks PM, Brady MJ. Rapid isolation and detection of drugs in meconium of infants of drug-dependent mothers. Clin Chem. 1988;34:2372-2373.
23. Koren G, Chan D, Klein J, et al. Estimation of fetal exposure to drugs of abuse, environmental tobacco smoke, and ethanol. Ther Drug Monit. 2002;24:23-25.
24. Pichini S, Pacifici R, Pellegrini M, et al. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of opiates and cocaine in meconium. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;794:281-292.
25. Pichini S, Pellegrini M, Pacifici R, et al. Quantification of arecoline (areca nut alkaloid) in neonatal biological matrices by high-performance liquid chromatography/electrospray quadrupole mass spectrometry. Rapid Commun Mass Spectrom. 2003;17:1958-1964.
26. Pichini S, Pacifici R, Pellegrini M, et al. Development and validation of a high-performance liquid chromatography-mass spectrometry assay for determination of amphetamine, methamphetamine, and methylenedioxy derivatives in meconium. Anal Chem. 2004;76:2124-2132.
27. Pichini S, Marchei E, Pacifici R, et al. Application of a validated high-performance liquid chromatography-mass spectrometry assay to the analysis of m- and p-hydroxybenzoylecgonine in meconium. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;820:151-156.
28. ElSohly MA, Feng S. delta 9-THC metabolites in meconium: identification of 11-OH-delta 9-THC, 8 beta,11-diOH-delta 9-THC, and 11-nor-delta 9-THC-9-COOH as major metabolites of delta 9-THC. J Anal Toxicol. 1998;22:329-335.
29. ElSohly MA, Stanford DF, Murphy TP, et al. Immunoassay and GC-MS procedures for the analysis of drugs of abuse in meconium. J Anal Toxicol. 1999;23:436-445.
30. Feng S, ElSohly MA, Salamone S, et al. Simultaneous analysis of delta 9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity extraction procedure. J Anal Toxicol. 2000;24:395-402.
31. Moore C, Negrusz A, Lewis D. Determination of drugs of abuse in meconium. J Chromatogr B Biomed Sci Appl. 1998;713:137-146.
32. Ostrea EM Jr, Lynn SM, Wayne RN, et al. Tissue distribution of morphine in the newborns of addicted monkeys and humans. Clinical implications. Dev Pharmacol Ther. 1980;1:163-170.
33. Montgomery D, Plate C, Alder SC, et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol. 2006;26:11-14.
34. Ostrea EM Jr, Brady M, Gause S, et al. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics. 1992;89:107-113.
35. Ostrea EM Jr, Romero A, Yee H. Adaptation of the meconium drug test for mass screening. J Pediatr. 1993;122:152-154.
36. Ostrea EM Jr, Matias O, Keane C, et al. Spectrum of gestational exposure to illicit drugs and other xenobiotic agents in newborn infants by meconium analysis. J Pediatr. 1998;133:513-515.
37. Ostrea EM Jr. Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Curr Probl Pediatr. 1999;29:37-56.
38. Ostrea EM Jr, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138:344-348.
39. Maynard EC, Amoruso LP, OHW. Meconium for drug testing. Am J Dis Child. 1991;145:650-652.
40. Browne S, Tebbett IR, Moore C, et al. Analysis of meconium for cocaine in neonates. J Chromatogr. 1992;575:158-161.
41. Browne S, Moore C, Negrusz A, et al. Detection of cocaine, norcocaine, and cocaethylene in the meconium of premature neonates. J Forensic Sci. 1994,39:1515-1519.
42. Rosengren SS, Longobucco DB, Bernstein BA, et al. Meconium testing for cocaine metabolite: prevalence, perceptions, and pitfalls. Am J Obstet Gynecol. 1993;168:1449-1456.
43. Wingert WE, Feldman MS, Kim MH, et al. A comparison of meconium, maternal urine and neonatal urine for detection of maternal drug use during pregnancy. J Forensic Sci. 1994;39:150-158.
44. Bibb KW, Stewart DL, Walker JR, et al. Drug screening in newborns and mothers using meconium samples, paired urine samples, and interviews. J Perinatol. 1995;15:199-202.
45. Ryan RM, Wagner CL, Schultz JM, et al. Meconium analysis for improved identification of infants exposed to cocaine in utero. Pediatrics. 1994;125:435-440.
46. Lewis D, Moore C, Leikin JB, et al. Multiple birth concordance of street drug assays of meconium analysis. Vet Hum Toxicol. 1995;37:318-319.
47. Samperiz S, Millet V, Arditti J, et al. Value of toxicological research in newborn infants of addicted mothers by the study of several samples (urine, meconium, hair). Arch Pediatr. 1996;3:440-444.
48. Stolk LM, Coenradie SM, Smit BJ, et al. Analysis of methadone and its primary metabolite in meconium. J Anal Toxicol. 1997;21:154-159.
49. Oyler J, Darwin WD, Preston KL, et al. Cocaine disposition in meconium from newborns of cocaine-abusing mothers and urine of adult drug users. J Anal Toxicol. 1996;20:53-62.
50. Xia Y, Wang P, Bartlett MG, et al. An LC-MS-MS method for the comprehensive analysis of cocaine and cocaine metabolites in meconium. Anal Chem. 2000;72:764-771.
51. Coles R, Clements TT, Nelson GJ, et al. Simultaneous analysis of the Delta9-THC metabolites 11-nor-9-carboxy-Delta9-THC and 11-hydroxy-Delta9-THC in meconium by GC-MS. J Anal Toxicol. 2005;29:522-527.
52. Lester BM, ElSohly M, Wright LL, et al. The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. Pediatrics. 2001;107:309-317.
53. Bada HS, Das A, Bauer CR, et al. Gestational cocaine exposure and intrauterine growth: maternal lifestyle study. Obstet Gynecol. 2002;100:916-924.
54. Bauer CR, Shankaran S, Bada HS, et al. The Maternal Lifestyle Study: drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol. 2002;186:487-495.
55. Pichini S, Puig C, Zuccaro P, et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the "Meconium Project." Forensic Sci Int. 2005;153:59-65.
56. Marchei E, Pellegrini M, Pacifici R, et al. Quantification of Delta-9-tetrahydrocannabinol and its major metabolites in meconium by gas chromatographic-mass spectrometric assay: assay validation and preliminary results of the "meconium project". Ther Drug Monit. 2006;28:700-706.
57. Lozano J, Garcia-Algar O, Marchei E, et al. Prevalence of gestational exposure to cannabis in a Mediterranean city by meconium analysis. Acta Paediatr. 2007; (Epub ahead to print).
58. Vinner E, Vignau J, Thibault D, et al. Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome. Ther Drug Monit. 2003;25:421-432.
59. Vinner E, Vignau J, Thibault D, et al. Hair analysis of opiates in mothers and newborns for evaluating opiate exposure during pregnancy. Forensic Sci Int. 2003;133:57-62.
60. Bar-Oz B, Klein J, Karaskov T, et al. Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. Arch Dis Child Fetal Neonatal Ed. 2003;88:F98-F100.
61. Buchi KF, Zone S, Langheinrich K, et al. Changing prevalence of prenatal substance abuse in Utah. Obstet Gynecol. 2003;102:27-30.
62. Arria AM, Derauf C, Lagasse LL, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2006;10:293-302.
63. Chan D, Caprara D, Blanchette P, et al. Recent developments in meconium and hair testing methods for the confirmation of gestational exposures to alcohol and tobacco smoke. Clin Biochem. 2004;37:429-438.
64. Moore C, Jones J, Lewis D, et al. Prevalence of fatty acid ethyl esters in meconium specimens. Clin Chem. 2003;49:133-136.
65. Bearer CF, Santiago LM, O'Riordan MA, et al. Fatty Acid ethyl esters: quantitative biomarkers for maternal alcohol consumption. J Pediatr. 2005;146:824-830.
66. Ostrea E. Hernandez J, Bielawski D, et al. Fatty acid ethyl esters in meconium: are they biomarkers of fetal alcohol exposure and effect? Alcohol Clin Exp Res. 2006;30:1152-1159.
67. Bearer CF, Lee S, Salvator AE, et al. Ethyl linoleate in meconium: a biomarker for prenatal ethanol exposure. Alcohol Clin Exp Res. 1999;23:487-493.
68. Bearer CF, Jacobson JL, Jacobson SW, et al. Validation of a new biomarker of fetal exposure to alcohol. J Pediatr. 2003;143:463-469.
69. Moore C, Jones J, Lewis D, et al. Prevalence of fatty acid ethyl esters in meconium specimens. Clin Chem. 2003;49:133-136.
70. Moore CM, Lewis D. Fatty acid ethyl esters in meconium: biomarkers for the detection of alcohol exposure in neonates. Clin Chim Acta. 2001;312:235-237.
71. Chan D, Bar-Oz B, Pellerin B, et al. Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. Ther Drug Monit. 2003;25:271-278.
72. Chan D, Klein J, Karaskov T, et al. Fetal exposure to alcohol as evidenced by fatty acid ethyl esters in meconium in the absence of maternal drinking history in pregnancy. Ther Drug Monit. 2004;26:474-481.
73. Klein J, Karaskov T, Koren G. Clinical applications of hair testing for drugs of abuse: the Canadian experience. Forensic Sci Int. 2003;10:281-288.
74. Bailey B, Klein J, Koren G. Noninvasive methods for drug measurement in pediatrics. Pediatr Clin North Am. 1997;44:15-26.
75. Harkey MR. Anatomy and physiology of hair. Forensic Sci Int. 1993;63:9-18.
76. Kintz P, Mangin P. Evidence of gestational heroin or nicotine exposure by analysis of fetal hair. Forensic Sci Int. 1993;63:99-104.
77. Kintz P, Villain M, Cirimele V. Hair analysis for drug detection. Ther Drug Monit. 2006;28:442-446.
78. Graham K, Koren G, Klein J, et al. Determination of gestational cocaine exposure by hair analysis. JAMA. 1989;262:3328-3330.
79. Kintz P, Mangin P. Determination of gestational opiate, nicotine, benzodiazepine, cocaine and amphetamine exposure by hair analysis. J Forensic Sci Soc. 1993;33:139-142.
80. Sallee FR, Katikaneni LP, McArthur PD, et al. Head growth in cocaine-exposed infants: relationship to neonate hair level. J Dev Behav Pediatr. 1995;16:77-81.
81. Katikaneni LD, Salle FR, Hulsey TC. Neonatal hair analysis for BZE: a sensitive and semiquantitative biological marker for chronic gestational cocaine exposure. Biol Neonate. 2002;81:29-37.
82. Strano-Rossi S, Chiarotti M, Fiori A, et al. Cocaine abuse in pregnancy: its evaluation through hair analysis of pathological newborns. Life Sci. 1996;59:1909-1915.
83. Ursitti F, Klein J, Koren G. Clinical utilization of the neonatal hair test for cocaine: a four-year experience in Toronto. Biol Neonate. 1997;72:345-351
84. Koren G, Klein J, McMartin K. Diagnosing intrauterine exposure to cocaine by hair testing: six years of clinical use. Ther Drug Monit. 1998;20:478-480.
85. Savitz DA, Henderson L, Dole N, et al. Indicators of cocaine exposure and preterm birth. Obstet Gynecol. 2002;99:458-465.
86. Areses R, Arruabarrena D, Alzueta MT, et al. Protocolos de Nefrología. 2002. Available at: http://www.aeped.es/protocolos/nefro/ index.htm. Accessed October 2007.
87. Sanaullah F, Gillian M, Lavin T. Screening of substance misuse during early pregnancy in Blyth: an anonymous unlinked study J Obstet Gynaecol. 2006;26:187-190.
88. Halstead AC, Godolphin W, Lockitch G, et al. Timing of specimen collection is crucial in urine screening of drug dependent mothers and newborns. Clin Biochem. 1988;21:59-61.
89. Osterloh JD, Lee BL. Urine drug screening in mothers and newborns. Am J Dis Child. 1989;143:791-793.
90. Schulman M, Morel M, Karmen A, et al. Perinatal screening for drugs of abuse: reassessment of current practice in a high-risk area. Am J Perinatol. 1993;10:374-377.
91. Mack G, Thomas D, Giles W, et al. Methadone levels and neonatal withdrawal. Paediatr Child Health. 1991;27:96-100.
92. Trivedy CR, Craig G, Warnakulasuriya S. The oral health consequences of chewing areca nut. Addict Biol. 2002;7:115-125.
93. Winstock A. Areca nut-abuse liability, dependence and public health. Addict Biol. 2002;7:133-138.
94. Moore CM, Brown S, Negrusz A, et al. Determination of cocaine and its major metabolite, benzoylecgonine, in amniotic fluid, umbilical cord blood, umbilical cord tissue, and neonatal urine: a case study. J Anal Toxicol. 1993;17:62.
95. Konkol RJ, Murphey LJ, Ferriero DM, et al. Cocaine metabolites in the neonate: potential for toxicity. J Child Neurol. 1994;9:242-248.
96. Dempsey DA, Partridge JC, Jones RT, et al. Cocaine, nicotine, caffeine, and metabolite plasma concentrations in neonates. J Anal Toxicol. 1998;22:220-224.
97. Callahan CM, Grant TM, Phipps P, et al, Measurement of gestational cocaine exposure. Sensitivity of infant's hair, meconium, and urine. J Pediatr. 1992;120:763-768.
98. Marques PR, Tippetts AS, Branch DG. Cocaine in the hair of motherinfant pairs: quantitative analysis and correlations with urine measures and self-report. Am J Drug Alcohol Abuse. 1993;19:159-175.
99. Potter S, Klein J, Valiante G, et al. Maternal cocaine use without evidence of fetal exposure. J Pediatr. 1994;125:652-654.
100. Doberczak TM, Kandall SR, Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol. 1993;81:936-940.
101. Knight EM, James H, Edwards CH, et al. Relationships of serum illicit drug concentrations during pregnancy to maternal nutritional status. J Nutr. 1994;124:973S-980S.
102. Cone EJ. Saliva testing for drugs of abuse. Ann N Y Acad Sci. 1993;694:91-127.
103. Kidwell DA, Holland JC, Athanaselis S. Testing for drugs of abuse in saliva and sweat. J Chromatogr B Biomed Sci Appl. 1998;713:111-135.
104. Jenkins AJ, Oyler JM, Cone EJ. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol. 1995;19:359-374.
105. Moolchan ET, Cone EJ, Wstadik A, et al. Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: plasma and saliva analysis. J Anal Toxicol. 2000;24:458-466.
106. Wolff K, Farrell M, Marsden J, et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction. 1999;94:1279-1298.
107. de la Torre R, Pichini S. Usefulness of sweat testing for the detection of cannabis smoke. Clin Chem. 2004;50:1961-1962.
108. Kintz P, Cirimele V, Ludes B. Codeine testing in sweat and saliva with the Drugwipe. Int J Legal Med. 1998;111:82-84.
109. Samyn N, van Haeren C. On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med. 2000;113:150-154.
110. Samyn N, de Boeck G, Verstraete AG. The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. J Forensic Sci. 2002;47:1380-1387.
111. Caplan YH, Goldberger BA. Alternative specimens for workplace drug testing. J Anal Toxicol. 2001;25:396-399.
112. Land DB, Kushner R. Drug abuse during pregnancy in an inner-city hospital: prevalence and patterns. J Am Osteopath Assoc. 1990;90:421-426.